Extended Data Fig. 8: Pharmacokinetics and organ protection of SK56 in septic mice.

a, Serum concentrations of SK56 were measured following intravenous administration (i.v.) of 1 mg/kg SK56 in mice. n = 2 mice. b, Stability of SK56 in human whole blood was evaluated at 37 °C for 12 hours (n = 4 repeats). c, ELISA results showing plasma IL-1β dynamics in low-dose LPS (15 mg/kg, i.p.) sepsis mice with or without SK56 (n = 10 mice). The purple arrow indicates the time of SK56 administration. d, H&E-stained histopathological sections showing damage to lung tissues (2-day post-treatment) LPS-treated WT and Gsdmd^−/− mice with or without SK56 (1 mg/kg i.v. n = 15 samples), along with the corresponding pathological score (right). Scale bars, 1 mm (whole section) and 50 µm (zoomed-in). e, H&E-stained histopathological sections illustrating damage to the kidneys, livers, intestines and spleens in WT or Gsdmd^−/− mice treated with or without SK56 (1 mg/kg, i.v.), along with the pathological score (n = 30 in LPS; n = 27 samples in CLP) of the kidneys. All graphs show mean ± s.d., and P values were calculated using two-tailed Student’s t-test, NS (P > 0.05, not significant).